A. B-lymphocyte
B. Megakaryocyte
C. T-lymphocyte
D. Natural killer - ANSWER A. B-lymphocyte
B lymphocytes synthesize and secrete immunoglobulins.
Which portion of the immunoglobulin activates the complement pathway?
A. MHC Class I
B. Fab
C. Fc
D. MHC Class II - ANSWER C. Fc
The Fc region activates the complement pathway.
Which of the following is a class II HLA antigen?
A. B
B. DR
C. A
1
,D. C - ANSWER B. DR
HLA DR, DQ and DP are class II antigens.
Which of the following is a disadvantage for the host of matched sibling/related donor stem
cells?
A. Delayed time to engraftment
B. Increased rate of infection
C. Limited number of cells available
D. Graft-versus-host disease - ANSWER D. Graft-versus-host disease
GVHD is a risk when using a matched sibling/related donor.
Which of the following statements by the nurse indicates an understanding of the teaching
regarding hematopoietic stem cells?
A. A high number are normally found in the peripheral circulation
B. They spend the majority of their life in an actively dividing state
C. A percentage of progenitor cells are self-renewing
D. They express protein markers on their cell surface - ANSWER D. They express protein
markers on their cell surface
Hematopoietic stem cells express protein markers on their cell surface that define the type
of cell and facilitate communication with other cells.
A pre-transplant patient asks about ABO compatibility with the donor. The nurse explains
that:
2
, A. there is less risk of GVHD.
B. the likelihood of engraftment is increased.
C. it is not essential for success.
D. compatibility is associated with better outcomes. - ANSWER C. it is not essential for
success.
ABO compatibility is not necessary for successful transplant
Which of the following factors affect the success of stem cell mobilization?
A. Vaccination history
B. Exposure to prior radiation
C. Prior pregnancies
D. Ethnic origin - ANSWER B. Exposure to prior radiation
Radiation may adversely affect the ability to achieve successful transplantation
Which of the following is an advantage of a non-myeloablative transplant?
A. Capitalize on the graft-versus-leukemia effect
B. Prevent the development of GVHD
C. Increase the efficacy in patients with high tumor burden
D. Decrease the incidence of graft rejection - ANSWER A. Capitalize on the graft-versus-
leukemia effect
Non-myeloablative transplants are indicated for patient where the GVL effect is the desired
outcome and is less toxic.
3